Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 21, 2006, Pages 5633-5638

  Chen, Jack J ^a   Thakur, Kumar D ^a   Clark, Michael P ^a   Laughlin, Steven K ^a   George, Kelly M ^a   Bookland, Roger G ^a   Davis, Jan R ^a   Cabrera, Edward J ^a   Easwaran, Vijay ^a   De, Biswanath ^a   George Zhang, Y ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

JAK2; JAK3; Pyrimidine; Tyrosine kinase inhibitor

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO] PYRROLO[2,3 D]PYRIMIDINE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50;

JANUS KINASE 3; PYRIMIDINES;

EID: 33748797725     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.022     Document Type: Article

References (11)

1. Silvennoinen O., Ihle J.N., Schlessinger J., and Levy D.E. Nature 366 (1993) 583
2. Thomis D., and Berg L. Curr. Opin. Immunol. 9 (1997) 541
3. O'Shea J.J., Pesu M., Borie D.C., and Changelian P.S. Nat. Rev. Drug Discov. 3 (2004) 555
4. Notarangelo L., Giliani S., and Mazza C. Immunol. Rev. 178 (2000) 39
5. O'Shea J.J. Ann. Rheumatic Dis. 63 (2004) ii67
6. Stepkowski S.M., Erwin-Cohen R.A., Behbod F., Wang M.-E., Qu X., Tejpal N., Nagy Z.S., Kahan B.D., and Kirken R.A. Blood 99 (2002) 680
7. Kudlacz E., Perry B., Sawyer P., Conklyn M., McCurdy S., Brissette W., Flanagan M., and Changelian P. Am. J. Transplant. 4 (2004) 51
8. Adams C., Aldous D.J., Amendola S., Bamborough P., Bright C., Crowe S., Eastwood P., Fenton G., Foster M., Harrison T.K.P., King S., Lai J., Lawrence C., Letallec J.-P., McCarthy C., Moorcroft N., Page K., Rao S., Redford J., Sadiq S., Smith K., Souness J.E., Thurairatnam S., Vine M., and Wyman B. Bioorg. Med. Chem. Lett. 13 (2003) 3105
9. ® Reagent) directly to a completed kinase reaction. This addition results in the generation of a luminescent signal correlated with the amount of ATP present and inversely proportional to the amount of kinase activity.
10. 50 = 6 nM).
11. 50s (Prism4 software).